JanOne develops non-addictive pain treatments: what it means for JanOne stock

Published on 10/07/2026 at 05:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Its JAN101 candidate targets pain linked to poor blood flow. JanOne stock focuses on non-addictive treatments for opioid-related disease.

JAN, US47089W1045, Illustration mit AI erstellt.

JanOne (ISIN US47089W1045) is developing non-addictive pain treatments, with JAN101 positioned around pain linked to inadequate blood flow in the limbs. The company's mission is to address diseases that cause severe pain while reducing reliance on opioid prescriptions, according to JanOne.

JAN101 gives the story a number

JanOne's lead candidate is described as an oral, extended-release sodium nitrite formulation intended to improve blood flow and address related pain. Danelfin identifies the company as a clinical-stage biopharmaceutical developer and names JAN101 as a central drug candidate.

The treatment concept gives the stock a distinctly development-driven profile: the commercial case depends on advancing a drug candidate rather than on an established product portfolio. That makes the treatment program, clinical progress and eventual market access central reference points for the company.

Historical quotes show wide context

Parqet listed JanOne at EUR 0.14 on June 24, 2026 and displayed a 32.03 percent yield. The same page identifies the security by ISIN US47089W1045, providing a dated European reference for the company behind the JAN ticker.

At Lang & Schwarz, the prior close for JanOne was EUR 0.40 on October 5, 2026. The difference between the June reference and the October prior close highlights the need to keep quote dates and venues separate when assessing this thinly followed biotechnology name.

Trading reference stays dated

JanOne's central investment question is whether JAN101 can progress from a clinical-stage candidate toward a commercially relevant treatment. The company's stated goal links that development path to two measurable needs: reducing severe pain and lowering dependence on addictive opioid therapies.

JanOne had a prior close of EUR 0.40 at Lang & Schwarz on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of JanOne stock.